Comparative Pharmacology
Head-to-head clinical analysis: POMBILITI versus THALIDOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMBILITI versus THALIDOMIDE.
POMBILITI vs THALIDOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
500 mg orally twice daily
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
None Documented
None Documented
Clinical Note
moderateThalidomide + Digoxin
"Thalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThalidomide + Digitoxin
"Thalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThalidomide + Deslanoside
"Thalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThalidomide + Acetyldigitoxin
"Thalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Category C
Category D/X
Immunomodulatory Agent
Immunomodulatory Agent